[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619395":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":23,"collaborators":11,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":29,"acronym":11,"eligibilityCriteria":30,"healthyVolunteers":31,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":11,"studyType":38,"phases":39,"briefSummary":41,"conditions":42,"keywords":46,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":11},{"fullName":5,"class":6},"Queen Savang Vadhana Memorial Hospital, Thailand","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"gynoflor group","EXPERIMENTAL",null,[13],"Drug: Gynoflor",{"label":15,"type":16,"description":11,"interventionNames":11},"control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Gynoflor","Participants in this group will receive Gynoflor vaginal tablets (containing Lactobacillus acidophilus and estriol) administered once daily for 7 consecutive days. This intervention aims to evaluate whether restoring vaginal flora with Gynoflor can prolong pregnancy time compared to no intervention.",[9],{"type":24,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100619395","the-effects-of-adjunctive-therapy-with-vaginal-tablets-lactobacillus-acidophilus-and-a-low-dose-estriol-gynoflor-to-prolong-pregnancy-time-in-preterm-labor-a-randomized-controlled-trial-100619395",false,"NCT07344064","The Effects of Adjunctive Therapy With Vaginal Tablets Lactobacillus Acidophilus and a Low Dose Estriol (Gynoflor®) to Prolong Pregnancy Time in Preterm Labor, A Randomized Controlled Trial","Inclusion Criteria\n\n\\- Pregnant women diagnosed with preterm labor or threatened preterm labor, with a gestational age between 24 and 33 weeks, who are receiving tocolytic therapy.\n\nExclusion Criteria\n\n* Age under 18 years or 35 years and older\n* Incomplete course of Gynoflor® (less than 6 days of use)\n* Presence of contraindications to tocolysis\n* Preterm premature rupture of membranes (PPROM)\n* Unable to be contacted for follow-up\n* History of allergy to probiotics or Gynoflor®\n* Multiple gestation\n* History of short cervix diagnosed between 16-24 weeks of gestation\n* History of previous preterm labor (PTL)\n* Pregnancy achieved via assisted reproductive technology (ART)\n* Presence of fetal anomaly\n* History of antepartum hemorrhage\n* Substance abuse, including cigarette smoking, alcohol, cocaine, or heroin use\n* Other causes of preterm labor such as uterine overdistension (e.g., polyhydramnios, multifetal gestation), uterine abnormalities (e.g., myoma uteri), or systemic infections, except vaginitis",true,"FEMALE","18 Years","35 Years",{"count":36,"type":37},80,"ESTIMATED","INTERVENTIONAL",[40],"NA","The study aim to study The Adjunctive therapy with vaginal tablets containing Lactobacillus acidophilus KS400 and low-dose Estriol (Gynoflor®) in addition to standard tocolytic treatment administered once daily for 6 days starting the same day as tocolytic therapy, in pregnant women diagnosed with preterm labor at gestational age 24-33 weeks .Primary Outcome is the rate of pregnancy prolongation beyond 7 days after initiation of tocolytic therapy.",[43,44,45],"Threaten Preterm","Prethrem Labour","Bacterial Vaginitis",[47,20,48,49,50],"Lactobacillus","Threaten preterm","Bacterial vaginitis","Probiotic","NOT_YET_RECRUITING","2026-01-07",{"date":54,"type":55},"2026-01-15","ACTUAL",{"date":57,"type":37},"2026-02",{"date":59,"type":37},"2026-10",{"name":5,"class":6}]